AU620253B2 - Creación de Inventos y Patentes con Inteligencia Artificial

AU620253B2 – Process for producing small particles of biologically active molecules
– Google Patents

AU620253B2 – Process for producing small particles of biologically active molecules
– Google Patents
Process for producing small particles of biologically active molecules

Download PDF
Info

Publication number
AU620253B2

AU620253B2
AU56359/90A
AU5635990A
AU620253B2
AU 620253 B2
AU620253 B2
AU 620253B2
AU 56359/90 A
AU56359/90 A
AU 56359/90A
AU 5635990 A
AU5635990 A
AU 5635990A
AU 620253 B2
AU620253 B2
AU 620253B2
Authority
AU
Australia
Prior art keywords
particles
molecules
solvent
biologically active
micrometers
Prior art date
1989-05-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
AU56359/90A
Other versions

AU5635990A
(en

Inventor
Henry E. Auer
Larry R. Brown
Wayne R. Gombotz
Michael S. Healey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alkermes Controlled Therapeutics Inc

Original Assignee
Enzytech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1989-05-01
Filing date
1990-05-01
Publication date
1992-02-13

1990-05-01
Application filed by Enzytech Inc
filed
Critical
Enzytech Inc

1990-11-29
Publication of AU5635990A
publication
Critical
patent/AU5635990A/en

1992-02-13
Application granted
granted
Critical

1992-02-13
Publication of AU620253B2
publication
Critical
patent/AU620253B2/en

1993-09-09
Assigned to ALKERMES CONTROLLED THERAPEUTICS, INC.
reassignment
ALKERMES CONTROLLED THERAPEUTICS, INC.
Alteration of Name(s) in Register under S187
Assignors: ENZYTECH, INC.

2010-05-01
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K9/00—Medicinal preparations characterised by special physical form

A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

A61K9/1682—Processes

A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K9/00—Medicinal preparations characterised by special physical form

A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

A61K9/1682—Processes

A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Abstract

Small diameter particles of biologically active molecules are produced by atomizing solutions of the molecules through a nozzle into very cold liquified gases, which immediately freeze the atomized droplets. The resulting frozen particles having diameters of approximately 10 to 90 micrometers are lyophilized to produce porous particles, suspended in a non-solvent for the molecules, and exposed to ultrasonic energy or homogenization to produce particles having diameters of 0.1 to 10 micrometers with greater than 70 to 95% of the initial biological activity of the molecules in solution.

Description

Signature of declarant(s) (no aftestation required) Note- Initial all alterations.
DAVIES COLLISON, MELBOURNE and CANBERRA.
-i ~1′ ‘1 OPQ DATE 29/11/90 6 2 0 DATE 10/01/91 APPLN. ID 56359 PCT NUMBER PCT/US90/02421 INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 5 (11) International Publication Number: WVO 90/13285 A61K 9/16, B01J 10/00 Al (43) International Publication Date: 15 November 1990 (15.11.90) (21) International Application Number: PCT/US90/02421 (74) Agents: PABST, Patrea, L. et al.; Kilpatrick Cody, 100 Peachtree Street, Suite 3100, Atlanta, GA 30303 (US).
(22) International Filing Date: 1 May 1990 (01.05.90) (81) Designated States: AT (European patent), AU, BE (Euro- Priority data: pean patent), CA, CH (European patent), DE (Euro- 345,684 1 May 1989 (01.05.89) US pean patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (Eu- (71) Applicant: ENZYTECH, INC. [US/US]; -763D-Goncord ropean patent), SE (European patent).
-A-venterGambridge°A -3l8 (US. i -U, (72)Inventors: GOMBOTZ, Wayne, R. 92 Marrett Road, Published Lexington, MA 02173 HEALY, Michael, S. 185 With international search report.
Walnut Street, East Bridgewater, MA 02333 Before the expiration of the time limit for amending the BROWN, Larry, R. 38 Cummings Road, Newton, MA claims and to be republished in the event of the receipt of 02159-1753 AUER, Henry, E. 805 Mt. Auburn amendments.
Street, #53, Watertown, MA 02172 (US).
o (54) Title: PROCESS FOR PRODUCING SMALL PARTICLES OF BIOLOGICALLY ACTIVE MOLECULES (57) Abstract Small diameter particles of biologically active molecules are produced by atomizing solutions of the molecules through a nozzle into very cold liquified gases, which immediately freeze the atomized droplets. The resulting frozen particles having diameters of approximately 10 to 90 micrometers are lyophilized to produce porous particles, suspended in a non-solvent for the molecules, and exposed to ultrasonic energy or homogenization to produce particles having diameters of 0.1 to 10 micrometers with greater than 70 to 95 of the initial biological activity of the molecules in solution.
i «ai^ See back of page -I 1 O 90/13285 PCT/US90/02421 PROCESS FOR PRODUCING SMALL PARTICLES OF BIOLOGICALLY ACTIVE MOLECULES BACKGROUND OF TIE INVENTION This invention relates to processes for producing particles of biological molecules at low temperatures using ultrasonic energy.
It is frequently desirable to incorporate biologically active proteins or other molecules within a polymeric matrix for use in controlled drug delivery or other applications requiring stable, uniform dispersions of material. Reduction of the particle size of such substances, particularly those that have biological activity such as proteins, is an important part in the design of pharmaceutical formulations.
For example, in the preparation of injectable polymeric microspheres for controlled drug delivery systems, the microspheres should be 50 micrometers or less in diameter. In order to achieve a i homogeneous distribution of drug particles throughout the matrix of the microsphere, the particles should have diameters much smaller i: than that of the microsphere itself. Smaller diameter particles loaded in such a system will result in more desirable release kinetics and can help eliminate the initial large amount of drug that is often released (the «burst effect») from these systems. By controlling the particle size of biological molecules in a controlled release device, one can also vary the release rate of drug from these systems, as described by Brown, et al., in «Controlled Release of Insulin from Polymer Matrices», Diabetes, 35, 684-691 (1986).
Most small particles of compounds to be used for pharmaceutical applications are prepared using conventional techniques such as spray dying, milling, grinding and lyophilization and sieving. Each of these techniques can reduce the particle size of the materials of interest, but the diameters are often not small enough for controlled release microsphere systems. These methods also have other disadvantages. Spray drying can reduce particles to sizes of five micrometers or less, but biologically active proteins can become S’ i 4I WO 90/13285 PCT/US90/02421 -2inactivated in the process due to denaturation at the aqueous air interface and by exposure to heat geinerated to evaporate the solvent.
Spray drying is also inefficient and much imaterial is lost due to sticking to the large surface area of the apparatus.
Milling and grinding can produce particles having diameters of only five micrometers, however, many of the particles are much larger in size. Because milling and grinding both require large amounts of material, these techniques are not very amenable to expensive biologically active proteins which can often be obtained only in small amounts. Milling and grinding can also result in denaturation of proteins. Sieving of lyophilized powders results in particle sizes of about 70 micrometers or greater.
It is therefore an object of the present invention to provide a method for producing small particles of biological molecules.
It is a further object of the present invention to provide particles of biologically active molecules that can be uniformly dispersed in a polymeric matrix for controlled release of the biologically active substance.
SUMMARY OF THE INVENTION A method for producing small particles of biologically active molecules ranging in diameter from approximately 0.1 to ten micrometers which retain greater than 70% to 95% of their original biological activity, wherein the yield of particles of the biologically :-ss active molecules is 80% or greater. The technique can be used to reduce the particle size in preparations of biologically active molecules, including macromolecules such as proteins or smaller molecules such as steroids, amino acids, or synthetic drugs, while maintaining the activity of the molecules. The process can also be used to reduce the particle size of other molecules that are not _1- WO 90/13285 PCT/US90/02421 -3biologically active, such as sugars or mixtures of these molecules with proteins.
The process for reducing the particle size of these compounds involves two principal steps. In the first step the molecules of interest are dissolved in a solvent and atomized into a low temperature liquified gas. The liquid gas is then evaporated, leaving frozen spherical particles containing solvent and the material of interest. The solvent is removed from the frozen spheres by lyophilization, resulting in the formation of porous spheres having diameters in the range of 10 to 60 micrometers. These spheres can be used as is, if larger particles are desired, or, if smaller particles are desired, they can be suspended in a non-solvent and exposed to ultrasonic energy or other mechanical forces to break the spheres into smaller particles having diameters in the range of from about 0.1 to 10 micrometers. The porous spherical particles or the smaller particles can be suspended in polymer or pharmaceutical carriersolvent solutions and entrapped for use in drug delivery systems since the particles can be homogeneously dispersed throughout the matrix, resulting in reproducible and controllable release kinetics.
‘BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic of the formation of porous spheres of biological molecules according to the method of the present invention.
Figure 2 is a schematic of the formation of small particles of biological molecules from the porous spheres of Figure 1 according to the method of the present invention.
Figure 3 is a graph of horse radish peroxidase particle size (micrometers) versus ultrasonication time (seconds), using the process of the present invention.
-i 1 1 1 WO 90/13285 PCI/US90/02421 -4- Figure 4 is a graph of the mean size (micrometers) for particles of dextran versus the concentration of dextran in solution when the particles are made using the processes of the present invention.
Figure 5 shows the spectra of the second derivative of absorption with respect to wavelength of fresh hemoglobin, hemoglobin treated with the particle size reduction process of the present invention and hemoglobin denatured in 6 M guanidinium chloride.
DETAILED DESCRIPTION OF THE INVENTION Many of the prior art methods for forming small particles of biological molecules either yield large diameter particles, result in loss of some of the material, or a cause a significant loss of biological activity. In contrast, the process of the present invention results in the size reduction of particles of biological molecules while maintaining greater than 70% of their original biological activity, and usually greater than 90-95% of the starting biological activity, as well as retaining 80% or more of the starting material.
Substances which can be used in this process include proteins, carbohydrates such as ne.tural or synthetic polysaccharides and sugars, nucleotides, and other biologically active inorganic and organic molecules having a wide range of molecular weights.
I-
Representative examples of biologically useful polypeptides include, Samong others, nucleoproteins, glycoproteins, and lipoproteins. Many protein classes are suitable for use in this process, including antibodies, enzymes, hormonally active polypeptides, immune modulators such as lymphokines, monokines, and cytokines, growth regulatory proteins, blood proteins, and antigens for viral, bacterial, and parasitic vaccines. Examples of other biological molecules that WO 90/13285 PCT/US90/02421 can be used in this process include steroids, lipids, synthetic and naturally occurring drugs, and amino acids.
The process is shown schematically in Figures 1 and 2.
As depicted in Figure 1, the biologically active molecule is first dissolved in a solvent to form a solution 10 having a concentration ranging from approximately 0.1 to 25% The solvent must be capable of being lyophilized. The solvent may be pure water or can be buffered to a particular pH or ionic strength.
The solvent may also be organic. The solution may contain a single type of molecule, mixtures of two or more types of molecules, mixtures of biologically active molecules and stabilizers, or any combination thereof. In order to reduce the particle size of certain molecules to the greatest extent, the molecule should be suspended in a medium in which not only the solvent but also the buffer salts are volatile under conditions of lyophilization. Examples of volatile buffers removed by lyophilization include ammonium bicarbonate and other ammonium salts.
The solution 10 is then atomized and the resulting droplets sprayed into a low temperature liquified gas 12 using any one of several devices 14, such as ultrasonic nozzles, pressure nozzles, pneumatic nozzles and rotary nozzles. The liquified gas 12 can be liquid argon (-185.6 0 liquid nitrogen (-195.8 0 liquid oxygen (-182.9″C) or any other liquid gas that results in the immediate freezing of the atomized particles into frozen particles The droplets freeze instantly upon entering the cold liquified gas. The liquified gas 12 is removed by evaporation at a temperature at which the solvent remains frozen, leaving behind frozen droplets of solvent and biologically active molecules 16. The frozen solvent is removed from the droplets 16 by lyophilization to yield porous spheres 18. These spheres can vary in diameter depending on the technique used for their atomization, but generally range from approximately 10 to 90 micrometers.
,L2 LI_ W090/13285 PCT/US90/02421 -6- This technique is particularly useful with proteins. When volatile buffer salts are used, the only solid remaining after lyophilization of the frozen spheres of solution containing the protein is the protein itself, with voids remaining in the space originally occupied by the volatile buffer. These voids minimize cohesion of protein-containing particles, permitting fragmentation of the protein particles into small pieces.
The porous spheres 18 can be used without further treatment if somewhat larger particle diameters are desirable. The porous spheres are useful in formulating polymeric drug delivery devices. When suspended in a polymer/solvent system in which the spheres 18 are not soluble, the result is a stable suspension 22 of the spheres 18. The choice of non-solvents that can be used for suspending the porous spheres depends on the nature of the molecules forming the spheres, as well as the polymer/solvent system. For proteins, exemplary non-solvents are acetone, ethyl acetate, methylene chloride, chloroform and tetrahydrofuran. The non-solvent for the porous spheres must be a solvent for the polymer. Exemplary polymer/solvent solutions in which proteins are not soluble include poly(lactic acid)/methylene chloride, poly(lactic-co-glycolic acid)/ethyl acetate and ethylene-vinyl acetate copolymer/methylene chloride.
Such suspensions can be formed into controlled release systems in the shape of injectable microspheres or implantable matrices. These systems can be bioerodible or non-erodible.
The porous particles can also be incorporated in elixirs for Smedications, aerosol sprays for delivery to the lungs or nasal epithelium, suppositories, tablets and transdermal delivery systems.
As shown in Figure 2, the size of the porous spheres 18 is further decreased by suspending the spheres 18 in a non-solvent such as ethanol, acetone, methylene chloride or ethyl acetate or any other solvent in which the molecules are not soluble. The suspension 22 is exposed to ultrasonic energy or other dispersive energy sources b v *i t Wo 90/13285 PCT/US90/02421 -7such as homogenization, with continuous cooling, for various times to break up the porous spheres. In general, it is not desirable to subject the particles to energy in excess of that required to produce a particular diameter particle. The longer the suspension 22 is exposed to the ultrasonic energy, the smaller the size of the particles 24. This process results in the size reduction of the spheres 18 to yield particles 24 having an approximate size range of 0.1 to 10 micrometers diameter.
By selecting a non-solvent for the molecules in the particles which is also a solvent for a particular polymer, this step can be varied to produce uniform dispersions of small particles in polymer solutions, for the subsequent entrapment or encapsulation of the particles in a polymeric matrix.
The particles 24 are then removed from the sonicated suspension 26 by conventional methods known to those skilled in the art such as filtration, centrifugation or sieving. If the particles have been reduced in size in a polymer/solvent system, they can then be formed into devices such as microspheres, or processed into tablets, elixirs, aerosol sprays, suppositories or transdermal devices, using methods known to those skilled in the art.
The present invention will be further understood from the following non-limiting examples.
Example 1: Production of Horse Radish Peroxidase Particles having diameters of less than five micrometers as a function of ultrasonication time.
A 250 mg sample of the enzyme horse radish peroxidase (HRP) (Sigma Chemical Co, St. Louis, MO.) was dissolved in 10 ml of a 0.05 M phosphate buffer solution having a pH of 7.2. The solution was atomized through an ultrasonic nozzle (SonoTek Corp., Model 8700-60MS) into a stirred container of liquid nitrogen. The liquid nitrogen containing the frozen atomized spheres was next placed in a 0 C freezer until the liquid nitrogen evaporated, about one to two WO 90/13285 PCT/US90/02421 -8hours. The frozen protein spheres were then placed in a lyophilizer (Virtis Company Inc., Model 10-MR-TR) for at least 12 hours to produce porous particles. After lyopilization the diameter of the HRP spheres was determined by light microscopy to be within a range of 25-35 micrometers.
A 50 mg sample of the lyophilized microspheres was suspended in 5 ml of 100 percent ethanol solution and cooled in an ice water bath to 0OC. With continuous cooling, the HRP porous particles were then exposed to an ultrasonic probe (Virtis Company Inc., VirSonic 300) for different times. Samples were analyzed for particle size diameter on a Microtrac Model 7995 Small Particle Analyzer (Leeds and Northrup). Figure 3 shows the mean particle size plotted as a function of time of ultrasonication. Particle size decreased to under five micrometers after 100 seconds.
The activity of the HRP was determined after the lyophilization step and after the ultrasonication step. The method used to determine the enzyme activity is based upon the rate of oxidation of p-anisidine and is described in detail in The Worthington Enzyme Manual, Worthington, Worthington Biochemical Corp., Freehold, NJ, p. 254 (1988). The HRP retained 90% or more of its original activity after each step of the particle size reduction process, indicating that the particle size reduction process has minimal effect on the activity of HRP.
Example 2: Production of Zinc Insulin Particles having diameters of less than four micrometers.
SThe procedure in Example 1 was repeated using zinc insulin (American International Chemical, Inc., Natick, MA) dissolved in a 1.05 M citrate-phosphate buffer at a pH of 5.2. The mean particle diameter after five minutes sonication was 3.2 micrometers.
f L i iI a~ WO 90/13285 PC7F/US90/02421
I
Examle 3: Production of Catalase Particles having diameters of less than five micrometers.
The procedure in Example 1 was repeated using catalase (Sigma Chemical The mean particle diameter after five minutes sonication was 4.5 3.3 micrometers.
Example 4: Production of Superoxide dismutase Particles having diameters of less than three micrometers.
The procedure in Example 1 was repeated using superoxide dismutase (America International Chemicals, Inc.). The mean particle diameter after five minutes sonication was 2.7 2.1 micrometers.
The activity of the SOD was determined after the lyophilization step and after the ultrasonication step. The method used to determine the enzyme activity is based upon the ability of SOD to inhibit the reduction of nitro-blue tetrazolium by the superoxide anion. This assay is described in detail by Winterbourne, et al., in The Estimation of Red Cell Superoxide Dismutase Activity,» J. Lab. Clin. Med., 85, 337 (1975). After the lyophilization step, the SOD had 94% of its original activity. After the ultrasonication step, the SOD has 91% of its original activity. This indicates that the particle size reduction process has minimal effect on the activity of
SOD.
Example 5: Production of Heparin Particles having diameters of less than seven micrometers.
The procedure in Example 1 was repeated with all the conditions as described except that the macromolecule used was heparin (Diosinth, Inc.) dissolved in deionized water. The mean particle diameter after five minutes sonication was 6.9 micrometers.
I
WO 90/13285 PCT/US90/02421 Example 6: Production of Hemoglobin Particles having diameters of less than two micrometers.
The procedure in Example 2 was repeated using bovine hemoglobin (Sigma Chemical The mean particle diameter after five minutes sonication was 1.8 1.3 micrometers.
Example 7: Production of Hemoglobin Particles having diameters of less than two micrometers using liquid argon.
The procedure in Example 6 was repeated with all the conditions described except that the hemoglobin solution was sprayed into liquid argon before lyophilization. The mean particle diameter after 5 minutes sonication was 3.6 2.8 micrometers.
Example 8: Production of HRP Particles having diameters of less than five micrometers as a function of pH.
The procedure in Example 1 was repeated with all the conditions as described except that three different buffers with different pH’s were used to dissolve the HRP: a citrate/phosphate buffer, pH 5.2; a phosphate buffer, pH 7.2 and a tris buffer, pH 9.1.
The lyophilized particles were sonicated for 5 min and their particle size determined, as shown in Table 1.
TABLE 1: Particle Size of Sonicated HRP as a function of Buffer pH.
Buffer pH Particle Size (uM) 5.2 2.9 2.1 7.2 3.5 2.8 9.1 6.2 3.7
.K
WO 90/13285 PCT/US90/02421 -11- Example 9: Production of Dextran Particles having diameters of less than five micrometers as a function of initial dextran concentration.
The procedure in Example 1 was repeated using dextran (Sigma Chemical Co., mw 40,200) at concentrations of 20, 10, 5, 1, and 0.5 percent. The particle size of these samples was determined after being suspended in 100 percent ethanol and ultrasonicated for five minutes.
Figure 4 shows the mean particle size of the dextran as a function of the dextran solution concentration used to make the macromolecule spheres. The results demonstrate that the smallest particles are produced using 0.5 to 5% dextran solutions.
Example 10: Production of Superoxide dismutase-dextran Particles having diameters of less than seven micrometers.
A 125 mg sample of SOD and a 125 mg sample of dextran were dissolved in a 0.05 M citrate-phosphate buffer solution at a pH of 5.2. The aqueous solution was atomized into liquid nitrogen and processed as described in Example 1. The mean particle diameter after five minutes sonication was 6.9 6.5 micrometers.
Example 11: Production of Hemoglobin Particles having diameters of less than four micrometers using ammonium bicarbonate as a buffer component.
125 mg bovine hemoglobin dissolved in 5 ml 0.05 M ammonium bicarbonate was formed into particles by spraying and lyophilization, according to the procedure of Example 1. Scanning electron micrographs (SEM) of the particles showed spheres having an exterior film and a spongy interior, with sizes ranging from 15 to micrometers in diameter. A control solution containing only ammonium bicarbonate was also sprayed and lyophilized as described in Example 1. The absence of any solid residue after lyophilization demonstrated the volatility of the buffer salt under these conditions.
J PCr/US90/01421 WO 90/13285 -12- The hemoglobin particles were suspended in ethyl acetate and fragmented by subjecting them to ultrasonic irradiation with cooling by an ice bath. When the resulting particles were subjected to particle size analysis using a Leeds Northrup Microtrac small particle analyzer, the mean particle diameter was 3.7 2.8 micrometers. SEM of sonicated particles showed flat irregular plates with lengths on the order of 1.0 micrometer, with a thickness of 0.1 micrometer.
Example 12: Production of Hemoglobin Particles having diameters of less than seven micrometers using homogenization.
A portion of the spherical particles of hemoglobin prepared in Example 11 were fragmented by suspending them in ethyl acetate and homogenizing them using a homogenizer (Brinkmann Instruments Co., Switzerland), instead of by ultrasonic irradiation. Particle size analysis of the resulting fragmented particles gave a size distribution for the effective diameters after 80 sec of homogenization of 7.2 3.7 micrometers. After 300 sec of homogenization, the particle diameter size distribution was 6.6 3.7 micrometers.
The homogenized hemoglobin particles were stored in ethyl acetate for seven days, after which the solvent was decanted and the hemoglobin dried under vacuum at room temperature. The resulting solid was dissolved in 0.2 M sodium phosphate pH 7.7, and its heme absorptien compared with that of freshly dissolved bovine hemoglobin, as well as with hemoglobin denatured in 6 M guanidinium chloride, using a Hewlett Packard diode array spectrophotometer. In order to accentuate spectral features, the second derivative of absorption with respect to wavelength was obtained for each sample. The results are shown in Figure 5. The spectra demonstrate tilat the samples of fresh hemoglobin and hemoglobin processed by the method described herein are identical and differ drastically from the curve for denatured ‘i
V~
1 i -i i fragmenting the suspension of particles until particles having diameters of 0.1 to 10 micrometers are produced; and removing the particles from the non-solvent.
‘1 i WO 90/13285 PCT/US90/02421 -13hemoglobin, indicating that the particle reduction process does not cause significant alterations in the protein molecule.
Example 13: Production of Horse RadLh Peroxidase Particles having diameters of less than three micrometers using ammonium bicarbonate as a buffer component.
Horse radish peroxidase frozen particles were prepared and subjected to ultrasonic fragmentation as described for hemoglobin in Example 11. The size distribution for the effective diameters of the resulting particles was 2.8 2.2 micrometers. The HRP particles retained 90% of their activity during this process, as assayed by the method described in Example 1.
Example 14: Production of Bovine Serum Albumin Particles having diameters of less than two micrometers using ammonium bicarbonate as a buffer component.
Bovine serum albumin (BSA) was suspended in 0, 4, and 100 mg of ammonium bicarbonate/ml water to a concentration of mg BSA/ml, and protein particles prepared as described for hemoglobin in Example 11. Under light microscopy, the BSA particles prepared from BSA solutions in 100 mg ammonium bicarbonate/ml solution contained extremely filamentous, airy strands of protein. The particles prepared from BSA in the other ammonium bicarbonate solutions also appeared filamentous but were more dense.
The sample prepared from 100 mg ammonium bicarbonate/ ml was suspended in ethyl acetate and fragmented by ultrasonic irradiation. The resulting r-reparation gave a size distribution having more than 60% of the particles less than 1.7 micrometers in diameter. Under light microscopy virtually all the particles were less than 1 micrometer in size.
*f! See back of page 1 ii: WO 90/13285 PCT’/US90/02421 -14- Example 15: Production of Glycine Particles having a diameter of less than 3.5 micrometers.
A 2.5% solution of Glycine (EM Science) was prepared in deionized water. ‘This was ultrasonicated to form frozen particles which were lyophilized according to the procedure of Example 1.
Light microscopy revealed porous particles having a mean diameter of 24.4 14.6 micrometers. These porous particles were fragmented by ultrasonication for 4 min, producing particles having a mean diameter of 3.2 1.9 micrometers. This example demonstrates the utility of this particles for reducing the particle size of low molecular weight compounds such as glycine (75.07 daltons).
Example 16: Production of Testosterone Particles from 1,4 Dioxane having a diameter of less than five micrometers.
The procedure in example 1 was repeated using a solution of testosterone (Sigma Chemical Co.) in 1,4 dioxane. The resulting particles had a mean diameter of 5.4 2.9 micrometers, demonstrating the effectiveness of the procedure to prepare small particles of steroids in organic solvents.
Example 17: Production of Stable suspension of porous BSA Particles.
A 1.994 gm sample of bovine serum albumin (BSA) (Sigma Chemical Co.) was dissolved in 80 ml of deionized water, atomized through an ultrasonic nozzle into liquid nitrogen and lyophilized. The particle diameter of the porous spheres ranged from 20-30 micrometers.
Samples of these BSA particles were suspended in a percent solution of ethylene-vinyl acetate (USI Chemicals Co.) in methylene chloride, resulting in mixtures containing 5, 10 and percent by weight of protein. All of these solutions contained stable suspensions of the BSA and the BSA did not settle to the bottom of WO 90/13285 PCT/US90/02421 the solution with time. It is believed that the solvent diffuses into the porous particles, equalizing the density of the particles with that of the polymer-solvent solution.
Modifications and variations of the method for making biologically active, small diameter particles will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to come within the scope of the appended claims.
I I i -I c -L ii

Claims (11)

1. A process for making porous particles of biologically active molecules having a diameter of 0.1 and 10 micrometers comprising: providing a solution of biologically active molecules selected from the group consisting of carbohydrates, polysaccharides, nucleotides, inorganic compounds, organic molecules, polypeptides, nucleoproteins, glycoproteins, and lipoproteins, in a solvent that can be removed by lyophilization; .atomizing the solution into a liquified gas in a vessel to produce frozen particles containing biologically active molecules in combination with the solvent; removing the gas from the vessel containing the frozen particles; removing the solvent from the particles by S. the biologically active molecules; fragmenting the suspension of particles until particles having diameters of 0.1 to 10 micrometers are produced; and removing the particles from the non-solvent.

2. The process of claim 1 wherein the gas is selected from the group consisting of nitrogen, argon, and oxygen.

3. The process of claim 1 further comprising adjusting the pH, concentration and ionic strength of the solution.

4. The process of claim 3 wherein salts are used to buffer the solution which can be removed from lyophilization. 911202,mngbdat.00O4,56359-90.rsp,16 X I 11 l 4! -17- The process of claim 1 wherein the solution is atomized through an ultrasonic nozzle.

6. The process of claim 1 further comprising suspending the porous particles in a polymer-solvent solution selected from the group consisting of poly(lactic acid)/methylene chloride, poly(lactic-co-glycolic acid)/ethyl acetate and ethylene-vinyl acetate/methylene chloride.

7. The process of claim 1 further comprising encapsulating the particles in a polymeric matrix.

8. Porous particles of biologically active molecules having a diameter of between 10 and 50 micrometers, containing molecules having greater than 70% of the Sactivity of the molecules in solution prior to forming the particles, wherein the particles are produced by 8. providing a solution of biologically active 20 molecules selected from the group consisting of carbohydrates, polysaccharides, nucleotides, inorganic compounds, organic molecules, polypeptides, nucleoproteins, glycoproteins, and lipoproteins, in a solvent that can be removed by lyophilization; atomizing the solution into a liquified gas in a vessel to produce frozen particles containing biologically active molecules in combination with the solvent; removing the gas from the vessel containing the frozen particles; and removing the solvent from the particles by lyophilization to produce porous particles of biologically active molecules having a diameter of between 10 and 50 micrometers.

9. The porous particles of claim 8 further comprising a polymerdc matrix. S911202mgda..4. 635990.sp17 remoingthesolentfromtheparicls b lyphliato topoueprusprilso i» 18 The porous particles of claim 9 wherein the polymeric matrix is formed of poly(lactic acid), poly(lactic-co-glycolic acid), ethylene-vinyl acetate, copolymers and blends thereof.

11. Particles of biologically active molecules having a diameter of between 0.1 and 10 micrometers, containing molecules having greater than 70% of the activity of the molecules in solution prior to forming the particles, wherein the particles are produced by providing a solution of biologically active molecules selected from the group consisting of carbohydrates, polysaccharides, nucleotides, inorganic compounds, organic molecules, polypeptides, 15 nucleoproteins, glycoproteins, and lipoproteins, in a solvent that can be removed by lyophilization; atomizing the solution into a liquified gas in a vessel to produce frozen particles containing biologically active molecules ii, combination with the 20 solvent; e removing the gas from the vessel containing the frozen particles; removing the solvent from the particles by lyophilization to produce porous particles; suspending the porous particles in a non-solvent for the biologically active molecules; and fragmenting the porous particles into particles having diameters of 0.1 to 10 micrometers.

12. The porous particles of claim 11 further comprising a polymeric matrix.

13. The porous particles of claim 12 wherein the polymeric matrix is formed of poly(lactic acid), poly(lactic-co-glycolic acid), ethylene-vinyl acetate, copolymers and blends thereof. 911202,mgbdat004,56359-90.rsp,18 I fc :I i

AU56359/90A
1989-05-01
1990-05-01
Process for producing small particles of biologically active molecules

Expired

AU620253B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US34568489A

1989-05-01
1989-05-01

US345684

1999-06-30

Publications (2)

Publication Number
Publication Date

AU5635990A

AU5635990A
(en)

1990-11-29

AU620253B2
true

AU620253B2
(en)

1992-02-13

Family
ID=23356054
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU56359/90A
Expired

AU620253B2
(en)

1989-05-01
1990-05-01
Process for producing small particles of biologically active molecules

Country Status (10)

Country
Link

US
(1)

US6569458B1
(en)

EP
(1)

EP0432232B1
(en)

JP
(1)

JPH0739339B2
(en)

AT
(1)

ATE99546T1
(en)

AU
(1)

AU620253B2
(en)

CA
(1)

CA2030551C
(en)

DE
(1)

DE69005800T2
(en)

DK
(1)

DK0432232T3
(en)

ES
(1)

ES2062530T3
(en)

WO
(1)

WO1990013285A1
(en)

Families Citing this family (148)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

FR2663223B1
(en)

1990-06-14
1994-12-02
Af Aplicaciones Far Lab

PARENTERAL GALENIC FORM.

DE4041563A1
(en)

1990-12-22
1992-06-25
Sanol Arznei Schwarz Gmbh

METHOD FOR PRODUCING ACTIVE MICROPARTICLES FROM HYDROLYTICALLY DEGRADABLE POLYMERS

US5912015A
(en)

1992-03-12
1999-06-15
Alkermes Controlled Therapeutics, Inc.
Modulated release from biocompatible polymers

US6514533B1
(en)

1992-06-11
2003-02-04
Alkermas Controlled Therapeutics, Inc.
Device for the sustained release of aggregation-stabilized, biologically active agent

CA2145418A1
(en)

1992-09-29
1994-04-14
John S. Patton
Pulmonary delivery of active fragments of parathyroid hormone

US7425543B2
(en)

1992-11-16
2008-09-16
The Corporation Of Mercer University
Microencapsulated materials and method of making same

ES2219646T5
(en)

1993-02-22
2008-11-01
Abraxis Bioscience, Inc.

METHODS FOR THE IN VIVO ADMINISTRATION OF BIOLOGICAL COMPOUNDS AND USEFUL COMPOSITIONS FOR THE SAME.

US5665382A
(en)

1993-02-22
1997-09-09
Vivorx Pharmaceuticals, Inc.
Methods for the preparation of pharmaceutically active agents for in vivo delivery

US5997904A
(en)

1993-02-22
1999-12-07
American Bioscience, Inc.
Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof

US5916596A
(en)

1993-02-22
1999-06-29
Vivorx Pharmaceuticals, Inc.
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

US6753006B1
(en)

1993-02-22
2004-06-22
American Bioscience, Inc.
Paclitaxel-containing formulations

US5439686A
(en)

1993-02-22
1995-08-08
Vivorx Pharmaceuticals, Inc.
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor

US5650156A
(en)

1993-02-22
1997-07-22
Vivorx Pharmaceuticals, Inc.
Methods for in vivo delivery of nutriceuticals and compositions useful therefor

US6528067B1
(en)

1993-02-22
2003-03-04
American Bioscience, Inc.
Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof

US5656597A
(en)

1993-04-28
1997-08-12
Akzo Nobel N.V.
Lyospheres comprising gonadotropin

EP0706374B1
(en)

1993-06-30
1997-12-10
Genentech, Inc.
Method for preparing liposomes

US20030113273A1
(en)

1996-06-17
2003-06-19
Patton John S.
Methods and compositions for pulmonary delivery of insulin

FR2720645B1
(en)

1994-06-03
1996-08-02
Oreal

Process for obtaining a raw material in the form of granules, raw material in the form of granules and its use in the cosmetic, hair, veterinary or pharmaceutical fields.

US6290991B1
(en)

1994-12-02
2001-09-18
Quandrant Holdings Cambridge Limited
Solid dose delivery vehicle and methods of making same

US5922253A
(en)

1995-05-18
1999-07-13
Alkermes Controlled Therapeutics, Inc.
Production scale method of forming microparticles

US6265389B1
(en)

1995-08-31
2001-07-24
Alkermes Controlled Therapeutics, Inc.
Microencapsulation and sustained release of oligonucleotides

CA2230494A1
(en)

1995-08-31
1997-03-06
Alkermes Controlled Therapeutics Inc.
Composition for sustained release of an agent

JP2893167B2
(en)

1995-09-29
1999-05-17
農林水産省東北農業試験場長

Container collection truck

IL120202A
(en)

1996-03-07
2001-03-19
Akzo Nobel Nv
Container with freeze-dried vaccine components

EP0904844A4
(en)

1996-06-10
2005-08-31
Nippon Telegraph & Telephone
Two-fluid nozzle and device employing the same nozzle for freezing and drying liquid containing biological substances

US20030035778A1
(en)

1997-07-14
2003-02-20
Robert Platz
Methods and compositions for the dry powder formulation of interferon

US5989463A
(en)

1997-09-24
1999-11-23
Alkermes Controlled Therapeutics, Inc.
Methods for fabricating polymer-based controlled release devices

US20060165606A1
(en)

1997-09-29
2006-07-27
Nektar Therapeutics
Pulmonary delivery particles comprising water insoluble or crystalline active agents

US6565885B1
(en)

1997-09-29
2003-05-20
Inhale Therapeutic Systems, Inc.
Methods of spray drying pharmaceutical compositions

EA002562B1
(en)

1997-09-29
2002-06-27
Инхэл Терапьютик Системз, Инк.
Perforated microparticles and methods of use

DK1061948T3
(en)

1998-03-20
2003-03-31
Takeda Chemical Industries Ltd

Preparation for sustained release of a physiologically active polypeptide and its preparation

FR2776520B1
(en)

1998-03-25
2000-05-05
Sod Conseils Rech Applic

NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PEPTIDES AND THEIR PREPARATION PROCESS

US6284282B1
(en)

1998-04-29
2001-09-04
Genentech, Inc.
Method of spray freeze drying proteins for pharmaceutical administration

JP2002527578A
(en)

1998-10-15
2002-08-27
ザ、プロクター、エンド、ギャンブル、カンパニー

Method for producing microporous granular material and detergent composition

EP1658840A1
(en)

1999-04-05
2006-05-24
Mannkind Corporation
Methods for fine powder formation

EP1165050B1
(en)

1999-04-05
2006-03-29
Mannkind Corporation
Methods for fine powder formation

US6444223B1
(en)

1999-05-28
2002-09-03
Alkermes Controlled Therapeutics, Inc.
Method of producing submicron particles of a labile agent and use thereof

US9006175B2
(en)

1999-06-29
2015-04-14
Mannkind Corporation
Potentiation of glucose elimination

SE9903236D0
(en)

1999-09-10
1999-09-10
Astra Ab

Method of obtaining microparticles

US6723347B1
(en)

1999-09-17
2004-04-20
Takeda Chemical Industries, Ltd.
Proces for producing protein powder

US6284283B1
(en)

1999-10-21
2001-09-04
Alkermes Controlled Therapeutics, Inc.
Method of producing sub-micron particles of biologically active agents and uses thereof

US6465425B1
(en)

2000-02-10
2002-10-15
Alkermes Controlled Therapeutics, Inc.
Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins

GB0004827D0
(en)

2000-02-29
2000-04-19
Quadrant Holdings Cambridge
Compositions

US7871598B1
(en)

2000-05-10
2011-01-18
Novartis Ag
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use

CA2382133C
(en)

2000-05-10
2010-11-23
Alliance Pharmaceutical Corporation
Phospholipid-based powders for drug delivery

US8404217B2
(en)

2000-05-10
2013-03-26
Novartis Ag
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use

US6565888B1
(en)

2000-08-23
2003-05-20
Alkermes Controlled Therapeutics, Inc.
Methods and compositions for the targeted delivery of biologically active agents

US6824822B2
(en)

2001-08-31
2004-11-30
Alkermes Controlled Therapeutics Inc. Ii
Residual solvent extraction method and microparticles produced thereby

EP1328260A2
(en)

2000-10-18
2003-07-23
Massachusetts Institute Of Technology
Methods and products related to pulmonary delivery of polysaccharides

GB0102075D0
(en)

2001-01-26
2001-03-14
Astrazeneca Ab
Process

US6862890B2
(en)

2001-01-30
2005-03-08
Board Of Regents, University Of Texas System
Process for production of nanoparticles and microparticles by spray freezing into liquid

ES2173047B1
(en)

2001-03-21
2004-01-01
Aplicaciones Farmacodinamicas

PROCEDURE FOR OBTAINING THE DIFFERENT FRACTIONS OF ATOMIZED GUAYABA AND ITS USE FOR THE TREATMENT OF MELLITUS TYPE II DIABETES

JP2004532277A
(en)

2001-06-08
2004-10-21
パウダージェクトワクチンズ，インコーポレーテッド

Spray freeze-dried composition

US20080026068A1
(en)

2001-08-16
2008-01-31
Baxter Healthcare S.A.
Pulmonary delivery of spherical insulin microparticles

CN1607941A
(en)

2001-11-19
2005-04-20
贝克顿迪肯森公司
Pharmaceutical compositions in particulate form

ES2364636T3
(en)

2001-12-19
2011-09-08
Novartis Ag

PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.

FR2834636B1
(en)

2002-01-15
2006-02-24
El Hassane Larhrib

PROCESS FOR THE MANUFACTURE OF HOLLOW MICRO-POROUS PARTICLES, ESPECIALLY FOR INHALATION

ES2300568T3
(en)

2002-03-20
2008-06-16
Mannkind Corporation

INHALATION APPARATUS

EP1610878B1
(en)

2003-02-21
2014-09-03
University Of Bath
Process for the production of particles

US20050048127A1
(en)

2003-07-22
2005-03-03
Larry Brown
Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof

US20080090753A1
(en)

2004-03-12
2008-04-17
Biodel, Inc.
Rapid Acting Injectable Insulin Compositions

SI2409707T1
(en)

2004-04-15
2015-07-31
Alkermes Pharma Ireland Limited
Polymer-based sustained release device

US7456254B2
(en)

2004-04-15
2008-11-25
Alkermes, Inc.
Polymer-based sustained release device

US8728525B2
(en)

2004-05-12
2014-05-20
Baxter International Inc.
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties

PL1786784T3
(en)

2004-08-20
2011-04-29
Mannkind Corp
Catalysis of diketopiperazine synthesis

KR20150039211A
(en)

2004-08-23
2015-04-09
맨카인드 코포레이션
Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery

US11246913B2
(en)

2005-02-03
2022-02-15
Intarcia Therapeutics, Inc.
Suspension formulation comprising an insulinotropic peptide

CA2604770C
(en)

2005-04-13
2013-09-24
Abbott Gmbh & Co. Kg
Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof

CA2604225A1
(en)

2005-04-27
2006-11-02
Baxter International Inc.
Surface-modified microparticles and methods of forming and using the same

AU2006290870B2
(en)

2005-09-14
2013-02-28
Mannkind Corporation
Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces

EP1976486A1
(en)

2006-01-27
2008-10-08
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin
A method of producing porous microparticles

AU2007216966C1
(en)

2006-02-22
2014-03-20
Mannkind Corporation
A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent

US20070281031A1
(en)

2006-06-01
2007-12-06
Guohan Yang
Microparticles and methods for production thereof

US20080075777A1
(en)

2006-07-31
2008-03-27
Kennedy Michael T
Apparatus and methods for preparing solid particles

CN101500616A
(en)

2006-08-04
2009-08-05
巴克斯特国际公司
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes

EP2049081B1
(en)

2006-08-09
2012-11-14
Intarcia Therapeutics, Inc.
Osmotic delivery systems and piston assemblies

MX2009003661A
(en)

2006-10-06
2009-04-22
Baxter Int
Microencapsules containing surface-modified microparticles and methods of forming and using the same.

EP1915987A1
(en)

2006-10-27
2008-04-30
MediGene AG
Spray-freeze-drying process for the preparation of pellets comprising percolation drying

KR101208381B1
(en)

2007-04-23
2012-12-05
인타르시아 세라퓨틱스 인코포레이티드
Suspension formulations of insulinotropic peptides and uses thereof

DK2240155T3
(en)

2008-02-13
2012-09-17
Intarcia Therapeutics Inc

Devices, formulations and methods for the delivery of several beneficial agents

CN102112118A
(en)

2008-04-25
2011-06-29
北卡罗来纳-查佩尔山大学
Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates

US8485180B2
(en)

2008-06-13
2013-07-16
Mannkind Corporation
Dry powder drug delivery system

US9358352B2
(en)

2008-06-13
2016-06-07
Mannkind Corporation
Dry powder drug delivery system and methods

AU2009257311B2
(en)

2008-06-13
2014-12-04
Mannkind Corporation
A dry powder inhaler and system for drug delivery

US9364619B2
(en)

2008-06-20
2016-06-14
Mannkind Corporation
Interactive apparatus and method for real-time profiling of inhalation efforts

CN102170902B
(en)

2008-08-01
2015-07-15
伽玛疫苗有限公司
Influenza vaccines

TWI614024B
(en)

2008-08-11
2018-02-11
曼凱公司
Use of ultrarapid acting insulin

US8323685B2
(en)

2008-08-20
2012-12-04
Baxter International Inc.
Methods of processing compositions containing microparticles

US20100047292A1
(en)

2008-08-20
2010-02-25
Baxter International Inc.
Methods of processing microparticles and compositions produced thereby

US8367427B2
(en)

2008-08-20
2013-02-05
Baxter International Inc.
Methods of processing compositions containing microparticles

US8323615B2
(en)

2008-08-20
2012-12-04
Baxter International Inc.
Methods of processing multi-phasic dispersions

US8721583B2
(en)

2008-10-31
2014-05-13
The Invention Science Fund I, Llc
Compositions and methods for surface abrasion with frozen particles

US8568363B2
(en)

2008-10-31
2013-10-29
The Invention Science Fund I, Llc
Frozen compositions and methods for piercing a substrate

US9060934B2
(en)

2008-10-31
2015-06-23
The Invention Science Fund I, Llc
Compositions and methods for surface abrasion with frozen particles

US8414356B2
(en)

2008-10-31
2013-04-09
The Invention Science Fund I, Llc
Systems, devices, and methods for making or administering frozen particles

US9060931B2
(en)

2008-10-31
2015-06-23
The Invention Science Fund I, Llc
Compositions and methods for delivery of frozen particle adhesives

US8545855B2
(en)

2008-10-31
2013-10-01
The Invention Science Fund I, Llc
Compositions and methods for surface abrasion with frozen particles

US8731841B2
(en)

2008-10-31
2014-05-20
The Invention Science Fund I, Llc
Compositions and methods for therapeutic delivery with frozen particles

US8545856B2
(en)

2008-10-31
2013-10-01
The Invention Science Fund I, Llc
Compositions and methods for delivery of frozen particle adhesives

US8409376B2
(en)

2008-10-31
2013-04-02
The Invention Science Fund I, Llc
Compositions and methods for surface abrasion with frozen particles

US8603496B2
(en)

2008-10-31
2013-12-10
The Invention Science Fund I, Llc
Compositions and methods for biological remodeling with frozen particle compositions

US9072799B2
(en)

2008-10-31
2015-07-07
The Invention Science Fund I, Llc
Compositions and methods for surface abrasion with frozen particles

US8551506B2
(en)

2008-10-31
2013-10-08
The Invention Science Fund I, Llc
Compositions and methods for administering compartmentalized frozen particles

US20100111857A1
(en)

2008-10-31
2010-05-06
Boyden Edward S
Compositions and methods for surface abrasion with frozen particles

US9050070B2
(en)

2008-10-31
2015-06-09
The Invention Science Fund I, Llc
Compositions and methods for surface abrasion with frozen particles

US8762067B2
(en)

2008-10-31
2014-06-24
The Invention Science Fund I, Llc
Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data

US8731840B2
(en)

2008-10-31
2014-05-20
The Invention Science Fund I, Llc
Compositions and methods for therapeutic delivery with frozen particles

US9060926B2
(en)

2008-10-31
2015-06-23
The Invention Science Fund I, Llc
Compositions and methods for therapeutic delivery with frozen particles

US20100111845A1
(en)

2008-10-31
2010-05-06
Searete Llc, A Limited Liability Corporation Of The State Of Delaware
Compositions and methods for therapeutic delivery with frozen particles

US8788211B2
(en)

2008-10-31
2014-07-22
The Invention Science Fund I, Llc
Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition

US8551505B2
(en)

2008-10-31
2013-10-08
The Invention Science Fund I, Llc
Compositions and methods for therapeutic delivery with frozen particles

US8603495B2
(en)

2008-10-31
2013-12-10
The Invention Science Fund I, Llc
Compositions and methods for biological remodeling with frozen particle compositions

US8725420B2
(en)

2008-10-31
2014-05-13
The Invention Science Fund I, Llc
Compositions and methods for surface abrasion with frozen particles

US9050317B2
(en)

2008-10-31
2015-06-09
The Invention Science Fund I, Llc
Compositions and methods for therapeutic delivery with frozen particles

US9072688B2
(en)

2008-10-31
2015-07-07
The Invention Science Fund I, Llc
Compositions and methods for therapeutic delivery with frozen particles

US8793075B2
(en)

2008-10-31
2014-07-29
The Invention Science Fund I, Llc
Compositions and methods for therapeutic delivery with frozen particles

US8563012B2
(en)

2008-10-31
2013-10-22
The Invention Science Fund I, Llc
Compositions and methods for administering compartmentalized frozen particles

US8314106B2
(en)

2008-12-29
2012-11-20
Mannkind Corporation
Substituted diketopiperazine analogs for use as drug delivery agents

US20100178038A1
(en)

2009-01-12
2010-07-15
Mediatek Inc.
Video player

US20100189800A1
(en)

2009-01-23
2010-07-29
Peter Markland
Continous double emulsion process for making microparticles

US9060927B2
(en)

2009-03-03
2015-06-23
Biodel Inc.
Insulin formulations for rapid uptake

PL2405963T3
(en)

2009-03-11
2014-04-30
Mannkind Corp
Apparatus, system and method for measuring resistance of an inhaler

MX2011013312A
(en)

2009-06-12
2012-01-25
Mankind Corp
Diketopiperazine microparticles with defined specific surface areas.

ES2650667T3
(en)

2009-09-28
2018-01-19
Intarcia Therapeutics, Inc

Rapid establishment and / or termination of substantial steady state drug administration

EP2496295A1
(en)

2009-11-03
2012-09-12
MannKind Corporation
An apparatus and method for simulating inhalation efforts

CN103328007B
(en)

2010-09-16
2016-09-21
北卡罗来纳州大学查珀尔希尔分校
Supporting agent and the asymmetric difunctionality silyl group monomer of prodrug and granule thereof is delivered as pharmaceutical agent, chemical reagent and biological reagent

EP2667891B1
(en)

2011-01-27
2021-10-06
Gamma Vaccines Pty Limited
Combination vaccines

US20120208755A1
(en)

2011-02-16
2012-08-16
Intarcia Therapeutics, Inc.
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers

SG194034A1
(en)

2011-04-01
2013-11-29
Mannkind Corp
Blister package for pharmaceutical cartridges

WO2012174472A1
(en)

2011-06-17
2012-12-20
Mannkind Corporation
High capacity diketopiperazine microparticles

AU2012328885B2
(en)

2011-10-24
2017-08-31
Mannkind Corporation
Methods and compositions for treating pain

AU2013289957B2
(en)

2012-07-12
2017-02-23
Mannkind Corporation
Dry powder drug delivery systems and methods

EP2911690A1
(en)

2012-10-26
2015-09-02
MannKind Corporation
Inhalable influenza vaccine compositions and methods

WO2013071316A2
(en)

2012-12-28
2013-05-16
Starbard Nathan T
Porous polymeric particles and methods of making and using them

ES2928365T3
(en)

2013-03-15
2022-11-17
Mannkind Corp

Microcrystalline diketopiperazine compositions, methods of preparation and use thereof

CN114848614A
(en)

2013-07-18
2022-08-05
曼金德公司
Heat stable dry powder pharmaceutical compositions and methods

JP2016530930A
(en)

2013-08-05
2016-10-06
マンカインドコーポレイション

Ventilation device and method

US10307464B2
(en)

2014-03-28
2019-06-04
Mannkind Corporation
Use of ultrarapid acting insulin

JP6628299B2
(en)

2014-08-25
2020-01-08
国立研究開発法人物質・材料研究機構

Particle forming method and particles

US9889085B1
(en)

2014-09-30
2018-02-13
Intarcia Therapeutics, Inc.
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c

US10561806B2
(en)

2014-10-02
2020-02-18
Mannkind Corporation
Mouthpiece cover for an inhaler

MY191539A
(en)

2015-03-26
2022-06-30
Gpn Vaccines Pty Ltd
Streptococcal vaccine

JP6993235B2
(en)

2015-06-03
2022-01-13
インターシアセラピューティクス，インコーポレイティド

Implant installation and removal system

MA53353A
(en)

2016-05-16
2021-06-09
Intarcia Therapeutics Inc

GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE

USD840030S1
(en)

2016-06-02
2019-02-05
Intarcia Therapeutics, Inc.
Implant placement guide

USD860451S1
(en)

2016-06-02
2019-09-17
Intarcia Therapeutics, Inc.
Implant removal tool

MX2019008006A
(en)

2017-01-03
2019-08-29
Intarcia Therapeutics Inc
Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug.

CN114160040B
(en)

2021-12-09
2022-07-12
广州风行乳业股份有限公司
Liquid nitrogen cryogenic granulation equipment

Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US2752097A
(en)

1951-03-03
1956-06-26

Microcyclomat Co

Method and apparatus for the production of fine and ultrafine particles

US4384975A
(en)

1980-06-13
1983-05-24

Sandoz, Inc.

Process for preparation of microspheres

EP0362582A2
(en)

1988-09-16
1990-04-11

Messer Griesheim Gmbh

Apparatus for granulating by freezing liquids

Family Cites Families (8)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3928566A
(en)

1970-08-14
1975-12-23
Du Pont
Lyophilized biological products

LU71110A1
(en)

1974-10-15
1976-11-11

DE2556561C2
(en)

1975-12-16
1983-04-14
Boehringer Mannheim Gmbh, 6800 Mannheim

Process for the production of porous tablets

US4096006A
(en)

1976-09-22
1978-06-20
Spectra-Strip Corporation
Method and apparatus for making twisted pair multi-conductor ribbon cable with intermittent straight sections

DE2659546A1
(en)

1976-12-30
1978-07-13
Boehringer Mannheim Gmbh

METHOD FOR PRODUCING FROZEN GRANULES

US4357259A
(en)

1977-08-01
1982-11-02
Northwestern University
Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres

US4479911A
(en)

1982-01-28
1984-10-30
Sandoz, Inc.
Process for preparation of microspheres and modification of release rate of core material

JPS59169504A
(en)

1983-03-18
1984-09-25
Fujirebio Inc
Preparation of freeze drying substance

1990

1990-05-01
AU
AU56359/90A
patent/AU620253B2/en
not_active
Expired

1990-05-01
WO
PCT/US1990/002421
patent/WO1990013285A1/en
active
IP Right Grant

1990-05-01
EP
EP90907640A
patent/EP0432232B1/en
not_active
Expired – Lifetime

1990-05-01
DK
DK90907640.8T
patent/DK0432232T3/en
active

1990-05-01
AT
AT90907640T
patent/ATE99546T1/en
not_active
IP Right Cessation

1990-05-01
CA
CA002030551A
patent/CA2030551C/en
not_active
Expired – Lifetime

1990-05-01
ES
ES90907640T
patent/ES2062530T3/en
not_active
Expired – Lifetime

1990-05-01
JP
JP2507661A
patent/JPH0739339B2/en
not_active
Expired – Fee Related

1990-05-01
DE
DE69005800T
patent/DE69005800T2/en
not_active
Expired – Lifetime

1993

1993-01-21
US
US08/006,682
patent/US6569458B1/en
not_active
Expired – Lifetime

Patent Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US2752097A
(en)

1951-03-03
1956-06-26
Microcyclomat Co
Method and apparatus for the production of fine and ultrafine particles

US4384975A
(en)

1980-06-13
1983-05-24
Sandoz, Inc.
Process for preparation of microspheres

EP0362582A2
(en)

1988-09-16
1990-04-11
Messer Griesheim Gmbh
Apparatus for granulating by freezing liquids

Also Published As

Publication number
Publication date

EP0432232B1
(en)

1994-01-05

JPH04500527A
(en)

1992-01-30

CA2030551A1
(en)

1990-11-02

JPH0739339B2
(en)

1995-05-01

WO1990013285A1
(en)

1990-11-15

EP0432232A1
(en)

1991-06-19

CA2030551C
(en)

1998-08-25

DE69005800T2
(en)

1994-05-19

ES2062530T3
(en)

1994-12-16

DE69005800D1
(en)

1994-02-17

AU5635990A
(en)

1990-11-29

US6569458B1
(en)

2003-05-27

ATE99546T1
(en)

1994-01-15

DK0432232T3
(en)

1994-01-31

Información de contacto